No Detail Found!

Unmasking the Malignant Threshold: Evidence-Based Immunohistochemical Panels for Detecting Pre-Malignant Gallbladder Lesions Across Global Healthcare Settings: A Systematic Review, Meta-Analysis and Resource-Stratified Tiered Framework

Author(s)
Naglaa A. Bayomy Department of Anatomy, College of Medicine, Northern Border University, 91431 Arar, Saudia Arabia
Anshoo Agarwal Department of Pathology, College of Medicine, Northern Border University, 91431 Arar, Saudi Arabia
Sadeem Fahad Alwulayi Faculty of Medicine, Northern Border University, 91431 Arar, Saudia Arabia
Asayel Saleh Alanzi Faculty of Medicine, Northern Border University, 91431 Arar, Saudia Arabia
Ghaliah Farraj Alanzi Faculty of Medicine, Northern Border University, 91431 Arar, Saudia Arabia
Rawan Sawab Albanaqi Faculty of Medicine, Northern Border University, 91431 Arar, Saudia Arabia
Danah Naif Salem Alanzi Faculty of Medicine, Northern Border University, 91431 Arar, Saudia Arabia
Nada Faleh AlRuwaili Faculty of Medicine, Northern Border University, 91431 Arar, Saudia Arabia
Abdelnaser Badawy Department of Medical Biochemistry, College of Medicine, Northern Border University, 91431 Arar, Saudi Arabia
Shereen M. Olama Department of Medicine, Faculty of Medicine, Northern Border University, 91431 Arar, Saudia Arabia; Departments of Rheumatology and Rehabilitation, Mansoura University Hospital, Mansoura, Egypt
Abstract
Background: Gallbladder Carcinoma (GBC) remains among the most lethal malignancies of the biliary tract, with poor outcomes largely driven by late-stage detection. The pre-malignant continuum spanning chronic cholecystitis with epithelial hyperplasia, intestinal and gastric metaplasia, Low-Grade Dysplasia (LGD) and High-Grade Dysplasia (HGD) offers a critical but underutilized window for early diagnosis. Immunohistochemistry (IHC) provides accessible, cost-effective and reproducible diagnostic tools; however, no internationally validated, tiered IHC panel has been developed specifically for pathology laboratories operating under resource constraints, as is common across South Asia, Latin America, the Middle East and sub-Saharan Africa, the very regions carrying the greatest GBC burden. Objectives: To systematically evaluate and pool published evidence on the diagnostic and prognostic accuracy of IHC markers and marker combinations for detecting, grading and prognosticating pre-malignant gallbladder lesions and to translate these findings into an evidence-based, tiered, resource-stratified panel suitable for deployment across diverse healthcare settings. Methods: Six electronic databases (PubMed/MEDLINE, EMBASE, CINAHL, Cochrane Library, Scopus, Web of Science) were searched for studies published between January 2000 and December 2024. Studies reporting IHC marker expression across the gallbladder carcinogenesis sequence were eligible, including tissue microarray, whole-section IHC and digital pathology designs. Quality was assessed using QUADAS-2 and the Newcastle-Ottawa Scale. Bivariate random-effects models yielded pooled sensitivity, specificity and AUROC estimates. PRISMA 2020 guidelines were followed throughout. Results: Seventynine studies encompassing 14,826 gallbladder specimens from 28 countries were included; 38 studies contributed sufficient data for meta-analyses. CDX2 achieved the highest diagnostic accuracy for intestinal metaplasia detection (pooled sensitivity 88.6%, specificity 92.1%; AUROC 0.947). The p53+Ki-67+CEA combination panel reached 91.3% sensitivity and 88.7% specificity for highgrade dysplasia/carcinoma discrimination, representing the most cost-effective trio for basic laboratory settings. Stepwise upregulation of p53 (normal: negative; LGD: 18-35%; HGD: 55-74%; GBC: 62-89%) and Ki-67 was consistently documented across studies. ECadherin loss correlated strongly with HGD/carcinoma transition (pooled specificity 86.4%). Substantial heterogeneity (I² = 32-62%) reflected variation in antibody clones, antigen retrieval protocols and histopathological classification systems. Conclusions: A threelevel tiered IHC panel framework is proposed: Tier 1 (p53, Ki-67, CEA, CK7, CK20) achievable at under USD 7 per case for district hospital settings; Tier 2 adding CDX2, E-Cadherin and MUC5AC for regional centers and Tier 3 incorporating MUC1, MUC2, SMAD4, HER2 and PD-L1 for tertiary academic institutions. Even the minimal Tier 1 panel has the potential to transform diagnostic yield for pre-malignant GBC detection in high-incidence, resource-constrained regions.
Publication Details
Page(s) 23-33
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 6, Year: 2026

Request the full text from PASTIC

Keywords
Biliary Tract Pathology, Pre-Malignant Lesions, Immunohistochemistry, MUC Proteins, Gallbladder carcinoma, IHC Panel, E-cadherin, P53, CDX2, Ki-67
References
Misra S. . .Carcinoma of the Gallbladder.” The Lancet Oncology. , 03(2003) : 01021-0.
Levy A.D. . .. Gallbladder Carcinoma: RadiologicPathologic Correlation.” Radiographics, 21(2001) : 295-314.
Sharma A. .2017 .. Gallbladder Cancer Epidemiology, Pathogenesis and Molecular Biology: An Update.” Asian Pacific Journal of Cancer Prevention, 18(2017) : 2339-2349.
Aretxabala De,X. De .2005 .Gallbladder Cancer: An Analysis of a Series of 139 Patients with Invasion Restricted to the Subserosal Layer. ” Journal of Gastrointestinal Surgery, 09(2006) : 186-192.
Roa I. . .Preneoplastic Lesions in Gallbladder Cancer. ” Journal of Surgical Oncology, 93(2006) : 615-623.
Lazcano-Ponce E.C. . .Epidemiology and Molecular Pathology of Gallbladder Cancer. CA: A Cancer Journal for Clinicians, 51(2001) : 349-364.
Patel T. .2002 .Worldwide Trends in Mortality from Biliary Tract Malignancies. ” BMC Cancer, 2 : 1471.
Kumari N.,January- N. .2014 .Mutation Profiling in Gallbladder Cancer in Indian Population. Indian Journal of Pathology and Microbiology, 57(1) : 130849-4929.
Saetta A.A. . .Mutational Analysis of BRAF in Gallbladder Carcinomas in Association with K-ras and p53 Mutations and Microsatellite Instability. Virchows Archiv, 445(2004) : 004-182.
Henson D.E. . .Carcinomas of the Pancreas, Gallbladder, Extrahepatic Bile Ducts and Ampulla of Vater Share a Field for Carcinogenesis: A Population-Based Study. Archives of Pathology & Laboratory Medicine, 133(2009) : 67-71.
Sasatomi E. . .Precancerous Conditions of Gallbladder Carcinoma: Overview of Histopathologic Characteristics and Molecular Genetic Findings. ” Journal of Hepato-BiliaryPancreatic Surgery, 7(2000) : 556-567.
Nakanuma Y. . .:AID-JEMT2>3.0. Microscopy Research and Technique, 38(19970915) : 2-0029.
Pilgrim C.H. .2013 .Modern Perspectives on Factors Predisposing to the Development of Gallbladder Cancer. ” HPB, 15(11) : 839-844.
Mondal S.K.,October -December .2017 .Histopathological Study of Gallbladder Carcinoma and Its Mimics with Role of Carcinoembryonic Antigen Immunomarker in Resolving Diagnostic Difficulties. Indian Journal of Medical and Paediatric Oncology, 230(4) : 15-415.
Chang H.J. . .Loss of Heterozygosity in Dysplasia and Carcinoma of the Gallbladder. ” Modern Pathology, 12(1999) : 00000478-769.
Wan X. .2017 .Gallbladder Papillary Neoplasms Share Pathological Features with Intraductal Papillary Neoplasm of the Bile Duct. ” Oncotarget, 8(19) : 31532-31539.
Wu X.S. . .Expression of Homeodomain Protein CDX2 in Gallbladder Carcinomas. ” Journal of Cancer Research and Clinical Oncology, 131(2005) : 271-278.
Kuraguchi M. .2006 .Adenomatous Polyposis Coli (APC) Is Required for Normal Development of Skin and Thymus. PLoS Genetics, 0020146(9) : .
Sugimachi K. . .The Role of Overexpression and Gene Amplification of Cyclin D1 in Intrahepatic Cholangiocarcinoma. ” Journal of Hepatology, 8278(01) : 0078-6.
Kanthan R. .2015 .Gallbladder Cancer in the 21st Century. ” Journal of Oncology, : .
Page M.J. .2021 .. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews.” BMJ, 372 : .
Higgins J.P.T. .2024 .. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5, updated August, : .
Wells G.A. .2022 .The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomised Studies in MetaAnalyses. , : .
DerSimonian N.,Laird N. . .. Meta-Analysis in Clinical Trials.” Controlled Clinical Trials, 7(86) : 90046-2.
Higgins J.P. .2003 .. Measuring Inconsistency in MetaAnalyses.” BMJ, 327(7414) : 557-560.
Roa I.,Patterns Spread .1999 .Gallbladder Cancer in a High Risk Area: Morphological Features. ” Hepatogastroenterology, 46(27) : 1540-1546.
Roa J.C. .2011 .. Squamous Cell and Adenosquamous Carcinomas of the Gallbladder: Clinicopathological Analysis of 34 Cases Identified in 606 Carcinomas.” Modern Pathology, 68(2011) : 1069-1078.
Ghosh M.,January -February .2013 .p53 and Beta-Catenin Expression in Gallbladder Tissues and Correlation with Tumor Progression in Gallbladder Cancer. Saudi Journal of Gastroenterology, 19(1) : 105922-3767.
Nakanuma Y.,Nagtegaal Y. .2019 .Cholangiocarcinoma.” WHO Classification of Tumours: Digestive System Tumours. , : 254-263.
Duffy A. . .Gallbladder Cancer (GBC): 10-Year Experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). ” Journal of Surgical Oncology, 98(2008) : 485-489.
Adsay N.V. .2012 .Pathologic Staging of Pancreatic, Ampullary, Biliary and Gallbladder Cancers: Pitfalls and Practical Limitations of the Current AJCC/UICC TNM Staging System and Opportunities for Improvement.” Seminars in Diagnostic Pathology. , 04(2012) : 127-141.
Stuart L.N. . .Analytic Validation of Immunohistochemistry Assays: New Benchmark Data from a Survey of 1085 Laboratories.” Archives of Pathology & Laboratory Medicine. , 141(2017) : 1255-1261.
Sirohi B. .2015 .Use of Gemcitabine-Based Chemotherapy in Indian Patients with Gallbladder Cancer. Future Oncology, 11(11) : 1575-1585.
Zou R.Q. .2022 .Comparison of Clinicopathological Characteristics of Mucinous Adenocarcinoma and Conventional Adenocarcinoma of Gallbladder. Asian Journal of Surgery, 03(2023) : 283-290.
Bhoge A. .2017 .Immunohistochemical Study of MUC1 and MUC5AC Expression in Gall Bladder Lesions. ” Journal of Clinical and Diagnostic Research, 11(7) : EC12-EC16.
Kong F.H. .2025 .. Mixed Adenoneuroendocrine Carcinoma of the Gallbladder: A Case Report and Literature Review.” Frontiers in Oncology, 1584744 : .
Benson A.B.,NCCN A.B. .2021 .Clinical Practice Guidelines in Oncology. ” Journal of the National Comprehensive Cancer Network, 0022(2021) : 541-565.
Corti F. .2018 .Targeting the PI3K/AKT/mTOR Pathway in Biliary Tract Cancers: A Review of Current Evidences and Future Perspectives.” Cancer Treatment Reviews. , 11 : 45-55.
Paweletz C.P. .2001 .. Reverse Phase Protein Microarrays Which Capture Disease Progression Show Activation of ProSurvival Pathways at the Cancer Invasion Front.” Oncogene, 1204265(16) : 1981-1989.
0

Citations

0

Downloads

16

Views